Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease
- Monday, March 6, 2023, 7:13
- Environment
- Add a comment
CHICAGO, March 6, 2023 /PRNewswire/ — Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines,…
About the Author
adminasapcorp has written 41538 stories on this site.